Pfizer

New York, New York, NY 10017

Public
Healthcare & Pharmaceuticals - Pharmaceuticals
over $1B
over 10K
(212) 733-2323
(302) 655-5049
media@pfizer.com


Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company's segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products. Its biotechnology products include BeneFIX, ReFacto and Xyntha. The Company's contract manufacturing business, Pfizer CentreOne, consists of its contract manufacturing and active pharmaceutical ingredient sales operation, including manufacturing and supply agreements with Zoetis Inc., and Hospira’s One-2-One sterile injectables contract manufacturing operation. Its research focuses on six areas, which include immunology and inflammatio... (Source: SEC reports)


Competitor - 1/7
Which company is more competitive with Pfizer?




3685 Contacts at this company
Eddy Nicolas
Associate Director, Executive Recruitment ...
Naveen Guniganti
Sr Manager
Michel Ginestet
Prsident de Pfizer France
Keith Mazza
Senior Director
Tasneem Patwa
Principal Scientist
Laura Hinds
Professional Sales Representative
Kinnari Pandya
Director
Draper Hall
Key Account Manager
Alyson Schutzbank
Operations Manager

Sep 20, 2018 19:18:44
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077, [...]

Sep 20, 2018 17:30:41
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077, [...]

Sep 18, 2018 19:18:48
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that additional sensitivity and post-hoc analyses from the Tafamidis [...]

Sep 18, 2018 19:12:50
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a [...]

Sep 18, 2018 17:30:47
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that additional sensitivity and post-hoc analyses from the Tafamidis [...]

Get Started Today : Sign up in 20 seconds
Search with 20+ criteria.
Export results in seconds.
Bad emails?
No worry, we give two extras for every bad email.